Fig. 4
Vaccination with TCL-loaded cDC1s protects against melanoma engraftment. a Schematic representation of treatment and analysis. PBS control or 0.5 × 106 poly I:C and autologous B16-OVA TCL-loaded cDC1s were intradermally (ID) injected 35 and 30 days prior to ID injection of 106 B16-OVA cancer cells (day 0) and tumor growth and survival monitored. b Tumor growth and c survival curve of mice treated as described in (a). Combined data of 2 independent experiments with total n = 14 (Control) and n = 13 (cDC1s) mice are shown. ***P < 0.001 by b Two-way ANOVA or c Mantel-Cox test